country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-188159

Copy Link Print Information

BMK-Y101

BMK-Y101 is a potent CDK kinase inhibitor. BMK-Y101 induces tumor cell apoptosis by inhibiting CDK kinases. BMK-Y101 can be used for research on hepatocellular carcinoma.

For research use only. We do not sell to patients.

CAS No.: 1314096-69-9
Formula: C₁₂H₁₄BrN₅O₅
Molecular Weight:388.17

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

BMK-Y101 Chemical Structure

CAS No.: 1314096-69-9

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

BMK-Y101 is a potent CDK kinase inhibitor. BMK-Y101 induces tumor cell apoptosis by inhibiting CDK kinases. BMK-Y101 can be used for research on hepatocellular carcinoma^[1]^[2]^[3].

IC₅₀ & Target

^[1]^[3]

CDK7

CDK9

CDK1

CDK2

All CDK Isoforms :

In Vitro

BMK-Y101 induces apoptosis in hepatocellular carcinoma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BMK-Y101 exhibits antitumor growth activity in hepatocellular carcinoma xenograft mouse models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Chemical Information

CAS No. 1314096-69-9
Molecular Weight 388.17
Formula C₁₂H₁₄BrN₅O₅
SMILES

O[C@H]1[C@H](O)[C@H](O[C@H]1CO)N2C=NC(N)=C3C2=NC(Br)=C3C(N)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. KIM Y J, et al. Selectivity between N-1 and N-7 nucleosides: regioselective synthesis of BMK-Y101, a potent cdk7 and 9 inhibitor. Tetrahedron Letters, 2013, 54(41): 5484-5488.

[2]. GANBOLD E O, et al. Raman spectroscopy and density functional theory study of energetically closely separated C2′‐endo and C3′‐endo pentose forms in purine nucleoside analogue drug‐gold conjugates. Journal of Raman Spectroscopy, 2018, 49(3): 424-430.

[3]. PERLÍKOVÁ P, et al. Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides [J]. MedChemComm, 2017, 8(12): 2213-2226.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote